Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ETNB NASDAQ:FULC NASDAQ:JANX NASDAQ:SDGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETNB89BIO$10.49-1.5%$9.79$4.16▼$11.84$1.53B1.281.54 million shs1.31 million shsFULCFulcrum Therapeutics$7.65-3.7%$6.95$2.32▼$10.13$412.94M2.37904,479 shs397,443 shsJANXJanux Therapeutics$26.40-4.9%$24.62$22.48▼$71.71$1.56B2.86878,789 shs908,736 shsSDGRSchrodinger$21.45-0.9%$21.94$16.60▼$28.47$1.57B1.58928,386 shs962,275 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETNB89BIO0.00%-4.64%+4.90%+73.10%+20.85%FULCFulcrum Therapeutics0.00%-2.30%+20.28%+132.52%-8.49%JANXJanux Therapeutics0.00%+4.97%+16.20%-11.08%-39.88%SDGRSchrodinger0.00%+2.09%+1.90%-16.70%-7.42%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationETNB89BIO2.1482 of 5 stars3.51.00.00.03.20.80.6FULCFulcrum Therapeutics0.6516 of 5 stars1.32.00.00.01.92.50.0JANXJanux Therapeutics2.2499 of 5 stars3.51.00.00.03.02.50.0SDGRSchrodinger2.0334 of 5 stars3.41.00.00.02.41.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceETNB89BIO 3.00Buy$26.43151.94% UpsideFULCFulcrum Therapeutics 2.50Moderate Buy$6.29-17.83% DownsideJANXJanux Therapeutics 3.08Buy$91.89248.06% UpsideSDGRSchrodinger 2.75Moderate Buy$32.7552.68% UpsideCurrent Analyst Ratings BreakdownLatest FULC, ETNB, SDGR, and JANX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025SDGRSchrodingerKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$32.00 ➝ $30.007/12/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)7/11/2025JANXJanux TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$65.007/3/2025SDGRSchrodingerMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight$28.006/27/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)6/11/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/29/2025FULCFulcrum TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$6.00 ➝ $9.005/24/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/23/2025FULCFulcrum TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/23/2025FULCFulcrum TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$4.00 ➝ $12.005/15/2025FULCFulcrum TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$10.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookETNB89BION/AN/AN/AN/A$3.34 per shareN/AFULCFulcrum Therapeutics$80M5.16N/AN/A$4.51 per share1.70JANXJanux Therapeutics$9.34M167.33N/AN/A$19.49 per share1.35SDGRSchrodinger$207.54M7.58N/AN/A$5.78 per share3.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateETNB89BIO-$367.08M-$3.38N/AN/AN/AN/A-81.44%-70.17%8/4/2025 (Estimated)FULCFulcrum Therapeutics-$9.73M-$0.07N/AN/AN/AN/A-0.20%-0.19%7/30/2025 (Estimated)JANXJanux Therapeutics-$68.99M-$1.36N/AN/AN/AN/A-9.29%-8.89%8/6/2025 (Estimated)SDGRSchrodinger-$187.12M-$2.63N/AN/AN/A-83.39%-44.74%-26.29%7/30/2025 (Estimated)Latest FULC, ETNB, SDGR, and JANX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025JANXJanux Therapeutics-$0.50N/AN/AN/A$0.30 millionN/A8/4/2025Q2 2025ETNB89BIO-$0.49N/AN/AN/AN/AN/A7/30/2025Q2 2025FULCFulcrum Therapeutics-$0.29N/AN/AN/AN/AN/A7/30/2025Q2 2025SDGRSchrodinger-$0.83N/AN/AN/A$52.03 millionN/A5/8/2025Q1 2025JANXJanux Therapeutics-$0.43-$0.38+$0.05-$0.38$0.59 millionN/A5/7/2025Q1 2025SDGRSchrodinger-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 million5/1/2025Q1 2025ETNB89BIO-$0.50-$0.49+$0.01-$0.49N/AN/A5/1/2025Q1 2025FULCFulcrum Therapeutics-$0.29-$0.28+$0.01-$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthETNB89BION/AN/AN/AN/AN/AFULCFulcrum TherapeuticsN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioETNB89BIO0.0618.0318.03FULCFulcrum TherapeuticsN/A28.7128.71JANXJanux TherapeuticsN/A58.4758.47SDGRSchrodingerN/A3.453.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipETNB89BION/AFULCFulcrum Therapeutics89.83%JANXJanux Therapeutics75.39%SDGRSchrodinger79.05%Insider OwnershipCompanyInsider OwnershipETNB89BIO2.60%FULCFulcrum Therapeutics7.00%JANXJanux Therapeutics8.10%SDGRSchrodinger8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableETNB89BIO40145.98 million142.19 millionOptionableFULCFulcrum Therapeutics10053.98 million50.20 millionOptionableJANXJanux Therapeutics3059.18 million54.38 millionOptionableSDGRSchrodinger79073.38 million67.07 millionOptionableFULC, ETNB, SDGR, and JANX HeadlinesRecent News About These CompaniesComparing Schrodinger (NASDAQ:SDGR) & Strata Skin Sciences (NASDAQ:SSKN)July 20 at 2:41 AM | americanbankingnews.comMaterial Informatics Company Evaluation Report 2025 | Schrodinger, Dassault Systèmes, and Citrine Informatics Drive Market Growth Through AI, Simulation, and CollaborationJuly 18 at 10:25 AM | globenewswire.comMassachusetts Financial Services Co. MA Sells 186,228 Shares of Schrodinger, Inc. (NASDAQ:SDGR)July 18 at 5:38 AM | marketbeat.comAjax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK TargetJuly 17 at 10:30 AM | finance.yahoo.comSchrodinger (NASDAQ:SDGR) Given New $30.00 Price Target at KeyCorpJuly 15, 2025 | americanbankingnews.comKeyCorp Has Lowered Expectations for Schrodinger (NASDAQ:SDGR) Stock PriceJuly 14, 2025 | marketbeat.comSchrodinger, Inc. (NASDAQ:SDGR) Position Raised by Stephens Investment Management Group LLCJuly 13, 2025 | marketbeat.comBMO Capital Remains a Buy on Schrodinger (SDGR)July 11, 2025 | theglobeandmail.comMorgan Stanley Assumes Coverage on Schrödinger (SDGR) StockJuly 10, 2025 | finance.yahoo.comAllspring Global Investments Holdings LLC Boosts Holdings in Schrodinger, Inc. (NASDAQ:SDGR)July 7, 2025 | marketbeat.comSDGR - Schrodinger Inc Ordinary Shares Financials - MorningstarJuly 5, 2025 | morningstar.comMMS initiates coverage on AI Biotechs, flags key pipeline catalystsJuly 3, 2025 | investing.comSchrödinger (SDGR) Receives FDA Fast Track Designation for Cancer Drug SGR-1505July 3, 2025 | msn.comMorgan Stanley Initiates Coverage on Schrodinger (NASDAQ:SDGR)July 3, 2025 | marketbeat.comSchrödinger, Inc. (SDGR) - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRJuly 2, 2025 | prnewswire.comShort SDGR: Schrödinger bounces from 2024 midpoint, trading range low as potential short-term targetJuly 1, 2025 | invezz.comISumitomo Mitsui Trust Group Inc. Sells 48,103 Shares of Schrodinger, Inc. (NASDAQ:SDGR)July 1, 2025 | marketbeat.comSchrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström MacroglobulinemiaJune 27, 2025 | tmcnet.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRJune 23, 2025 | globenewswire.com17,493 Shares in Schrodinger, Inc. (NASDAQ:SDGR) Bought by Palumbo Wealth Management LLCJune 23, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFULC, ETNB, SDGR, and JANX Company Descriptions89BIO NASDAQ:ETNB$10.49 -0.16 (-1.50%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$10.61 +0.12 (+1.14%) As of 07/18/2025 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Fulcrum Therapeutics NASDAQ:FULC$7.65 -0.29 (-3.65%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$7.64 -0.01 (-0.07%) As of 07/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Janux Therapeutics NASDAQ:JANX$26.40 -1.35 (-4.86%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$26.40 +0.01 (+0.02%) As of 07/18/2025 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Schrodinger NASDAQ:SDGR$21.45 -0.20 (-0.92%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$21.74 +0.29 (+1.33%) As of 07/18/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
